Haas, Clarissa B.
Lovászi, Marianna
Pacher, Pál
de Souza, Priscila Oliveira
Pelletier, Julie
Leite, Rafael Olive
Sévigny, Jean
Németh, Zoltán
Braganhol, Elizandra
Haskó, György
Funding for this research was provided by:
national institute of general medical sciences (R01GM06618916)
national institute of diabetes and digestive and kidney diseases (R01DK11379004)
coordenação de aperfeiçoamento de pessoal de nível superior (001)
instituto nacional de ciência e tecnologia da criosfera (400882/2019-1)
national institutes of health (P30CA013696)
Article History
Received: 16 June 2021
Accepted: 23 August 2021
First Online: 4 October 2021
Declarations
:
: G.H. owns stock in Purine Pharmaceuticals, Inc., and has a patent to develop NTPDases for the treatment of sepsis. The other authors have no financial conflict of interest.
: All animal experiments were approved by the Columbia University Institutional Animal Care and Use Committee. The human study protocol for blood collection from patients and healthy controls was approved by the Hospital Nossa Senhora da Conceição, Porto Alegre, Rio Grande do Sul, Brazil Research Ethics Committee (registration numbers 49959315.5.0000.5530 and 49959315.5.3001.5345, Brazilian National Ethical Committee-CONEP).
: Written informed consent was obtained from all the participants.